In particular, following the administration of a SGLT2 inhibitor to the moderate diabetes model, macula densa luminal [Cl−] along the superficial nephron is predicted to be 39.2 mM with the assumed GFR-lowering effect, and 51.4 mM without. Here, SLC5A2 is linked to diabetes mellitus.